Recent 8-K filings for ELUT
Highest-materiality recent filing
Elutia sells CIED business to Boston Scientific for up to $88M; funds breast reconstruction pipeline
- Asset sale of EluPro/CanGaroo bioenvelope business to Boston Scientific (BSX) for $80M at closing plus $8M escrow.
- Proceeds to eliminate outstanding debt, resolve Orthobiologics litigation, and fund NXT-41 advancement without dilution.
-
Elutia reports Q1 net loss $7.5M; NXT-41x on track for clearance in H1 2027
Net loss from continuing ops $7.9M vs $1.9M loss in Q1 2025; net loss $7.5M vs $3.9M.
-
Elutia Q4 revenue $3.3M (+16% YoY); NXT-41 510(k) submitted; cash $36.4M
Q4 2025 net sales from continuing ops $3.3M, up 16% YoY; adjusted gross margin 66.8%.
-
Elutia adopts 2026 Inducement Award Plan, authorizing up to 2M shares for new hire grants
Board adopted Inducement Plan on March 3, 2026; allows equity grants to new employees as hiring inducement without shareholder approval.
-
Elutia regains full compliance with Nasdaq minimum bid price and MVLS requirements
Received Nasdaq notice on March 2, 2026, confirming compliance with minimum bid price rule (bid ≥ $1.00 for 10 consecutive days).
-
Elutia reports preliminary Q4 2025 revenue $3.3M (+16% YoY); eliminates $26.9M debt
Preliminary Q4 net sales ~$3.3M, up 16% YoY, excluding divested BioEnvelope business.
-
Notice received Dec 23, 2025: MVLS below $35M for 30 consecutive business days.
-
Elutia receives Nasdaq deficiency notice for bid price below $1.00 per share
Nasdaq notified Elutia on Nov 7, 2025 that its common stock closed below $1.00 for 30 consecutive business days.
-
Elutia Q3 revenue $3.3M, closes $88M BioEnvelope sale to Boston Scientific, pays off debt
Net sales $3.3M (down from $3.7M YoY); loss from operations $5.2M vs $9.2M loss a year ago.
-
Elutia appoints medtech veteran Guido Neels to board; Jordan and Zuga resign
Guido J. Neels elected to board effective Oct 9, 2025; appointed to Audit Committee.
-
Elutia closes $88M sale of BioEnvelope business to Boston Scientific; pivots to NXT-41x
Closed sale of CIED/BioEnvelope business to Boston Scientific for $88M cash; $80.3M paid at closing, $8M escrowed for 12 months.
-
Elutia sells CIED business to Boston Scientific for up to $88M; funds breast reconstruction pipeline
Asset sale of EluPro/CanGaroo bioenvelope business to Boston Scientific (BSX) for $80M at closing plus $8M escrow.
-
Elutia amends SWK credit facility, capitalizes interest and fees into principal
Fifth Amendment to $25M senior secured term loan capitalizes accrued interest due Aug 2025, $50k amendment fee (June 30, 2025), and $10k amendment fee.
-
Elutia Q2 BioEnvelope revenue $3.5M (+33% YoY), EluPro sales surge 49% sequentially
EluPro drug-eluting envelope revenue up 49% sequentially; now ~2/3 of BioEnvelope sales; average per-customer spend 130% higher vs legacy CanGaroo.
-
Elutia annual meeting elects two Class II directors, ratifies PwC as auditor
29,585,703 shares (80.9% of outstanding) present at May 29, 2025 annual meeting.
-
Elutia Issues Shares to Ligand, Amends SWK Loan, and Reports 84% Sequential EluPro Growth
Issued 1,105,528 shares to Ligand Pharmaceuticals to satisfy $2.2 million in royalty obligations.
-
Elutia terminates LeMaitre distribution deal, moves to direct cardiovascular sales
Termination of distribution agreement with LeMaitre Vascular for ProxiCor, VasCure, Tyke products in the U.S.
-
Elutia Q4 2024: BioEnvelope sales +18% to $2.7M; EluPro pilot launch gains traction; net loss $9.1M
Q4 BioEnvelope sales $2.7M (+18% YoY); overall net sales $5.5M (-7% YoY) due to SimpliDerm and cardiovascular declines.
-
Elutia raises $15M in registered direct offering; sells 5.52M shares at $2.50/share
Gross proceeds of $15.0M from sale of 5,520,000 shares at $2.50 and 480,000 prefunded warrants at $2.499.
-
Elutia prelim FY2024 net sales $24.4M, down 1% YoY; cardiovascular sales plunge 42%
Preliminary 2024 net sales $24.4M vs $24.7M in 2023, a 1% decline.
-
Elutia Q3 net sales $5.9M (-3.3%); EluPro adoption accelerates with 100+ VAC submissions
Overall Q3 net sales $5.9M, down 3.3% YoY; BioEnvelope sales down 12% to $2.3M as customers await EluPro.
-
Elutia amends credit agreement, deferring principal repayments by one year to Nov 2025
Principal repayment commencement deferred from Nov 15, 2024 to Nov 15, 2025.
-
Elutia Q2 net loss widens to $28.2M on warrant revaluation; EluPro launch underway
Net loss $28.2M vs $10.6M YoY; includes $18.3M non-cash warrant revaluation charge.
-
Gross proceeds ~$13.26M from sale of 3,175,000 shares and 725,000 prefunded warrants.
-
FDA cleared EluPro, first antibiotic-eluting bioenvelope, for pacemakers, defibrillators, neurostimulators, and neuromodulators.
-
Elutia stockholders elect Maybelle Jordan and W. Matthew Zuga as Class I Directors at annual meeting
Turnout 12,975,682 shares (64.8% of outstanding Class A common stock) at June 6, 2024 annual meeting.
-
Elutia Q1 net sales $6.7M; SimpliDerm up 55%; CanGarooRM FDA decision expected by June 2024
SimpliDerm net sales $3.6M (+55% YoY) driven by accelerated adoption in $1.6B breast reconstruction market.
-
Elutia amends credit agreement, reducing minimum revenue covenant to $20M from $41M
Second Amendment with SWK Funding LLC lowers minimum Aggregate Revenue to $20M for trailing twelve months from Q1 2024 onward.
-
Elutia reports FY23 net loss $37.7M, cash $19.3M; CanGarooRM 510(k) decision expected H1 2024
Full year net sales $24.7M vs $23.8M; SimpliDerm up 38%, CanGaroo up 3.4%.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.65 · Most common event earnings